文献速递神经肿瘤

利用临床前模型开发罕见中枢神经系统癌症的靶向治疗

Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers.
PubMed 文献 · Neuro Oncol · 2021-01-01

本文综述了罕见中枢神经系统肿瘤临床前模型的优缺点,强调体外和离体模型用于靶点发现与机制研究、体内模型用于治疗验证。文中还总结了室管膜瘤、组蛋白突变高级别胶质瘤和非典型畸胎样横纹肌样瘤的模型构建与筛选进展,这些肿瘤近期已确立遗传或表观遗传驱动因素。

要点

  • 罕见中枢神经系统肿瘤预后差且治疗选择有限,患者数量少导致研究困难。
  • 近期技术进展已鉴定出部分罕见中枢神经系统癌症的分子驱动因素,可用于生成代表性临床前模型。
  • 临床前模型对推进这些目前依赖传统治疗的罕见中枢神经系统癌症的靶向治疗至关重要。

核心结论

  • 临床前模型对推进目前依赖传统治疗的罕见中枢神经系统癌症的靶向治疗至关重要。

研究设计与样本

  • 综述,概述不同临床前模型的优缺点,并重点总结室管膜瘤、组蛋白突变高级别胶质瘤和非典型畸胎样横纹肌样瘤的模型构建与筛选方法。

主要发现

  • 体外和离体模型有助于靶点发现和机制研究,多种体内模型可用于治疗验证。
  • 室管膜瘤、组蛋白突变高级别胶质瘤和非典型畸胎样横纹肌样瘤均为罕见中枢神经系统癌症,近期已确立遗传或表观遗传驱动因素。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with rare central nervous system (CNS) tumors typically have a poor prognosis and limited therapeutic options. Historically, these cancers have been difficult to study due to small number of patients. Recent technological advances have identified molecular drivers of some of these rare cancers which we can now use to generate representative preclinical models of these diseases. In this review, we outline the advantages and disadvantages of different models, emphasizing the utility of various in vitro and ex vivo models for target discovery and mechanistic inquiry and multiple in vivo models for therapeutic validation. We also highlight recent literature on preclinical model generation and screening approaches for ependymomas, histone mutated high-grade gliomas, and atypical teratoid rhabdoid tumors, all of which are rare CNS cancers that have recently established genetic or epigenetic drivers. These preclinical models are critical to advancing targeted therapeutics for these rare CNS cancers that currently rely on conventional treatments.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Arakaki AKS, Szulzewsky F, Gilbert MR, et al. Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers. Neuro Oncol. 2021. PMID: 34725698. doi:10.1093/neuonc/noab183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。